Syntekabio successfully concluded BioTechX USA 2024, where it participated as the title sponsor.
Syntekabio, an AI (artificial intelligence) drug development specialist company, announced on the 20th that it participated as the title sponsor in ‘BioTechX USA 2024,’ held from the 17th to 18th of this month (local time) in Pennsylvania, USA, to promote its AI drug development platform.
As the title sponsor, Syntekabio set up the largest sponsorship booth to introduce AI platforms for synthetic and biopharmaceutical drug development, including ▲DeepMatcher ▲NEO-ARS ▲AB-ARS.
On the morning of the opening day, the 17th, Dr. Jonathan Witztum, CTO of Syntekabio USA, delivered a keynote speech titled “Solving Data Scarcity Issues in Drug Discovery Using Physics-Based AI Models.” In the afternoon, CEO Jongseon Jeong gave a presentation on the use of AI in drug development, explaining flexible molecular docking for neoantigen and antibody drug prediction and its application in preclinical trials.
Syntekabio used this event as a starting point to actively promote its new service model, the DP program, globally. On-site visitors and potential clients showed great interest in the DP program’s new approach, especially its risk reduction effects.
Jongseon Jeong, CEO of Syntekabio, said, “This conference was an important opportunity to showcase our AI drug technology to the global market,” adding, “The strong interest in the DP program confirmed that market needs align with our strategy.”
He continued, “We have held cooperation discussions with numerous companies, and we expect the new business model to reduce risks and improve efficiency in our clients’ drug development. We anticipate sharing positive contract news after further concretization.”
Meanwhile, ‘BioTechX USA 2024’ is a conference covering digital innovation in diagnostics, drug development, and healthcare, featuring in-depth discussions and presentations on bio data, genomics, AI drug development, and chemoinformatics.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
